A novel regimen of vorinostat with interferon gamma for refractory Sezary syndrome
Gardner JM et al. - Long-term prognosis for advanced stages of cutaneous T-cell lymphoma may be beneficially altered with the use of multimodality therapy. However, refractory disease exists in which current therapeutic options fail to halt the progression of disease. The authors present 3 cases of refractory Sezary syndrome in which the combination of vorinostat and interferon gamma was well tolerated and produced significant clinical improvement. [more...]
|
|
|
